Besser

Quick links to important sections

Besser

Treatment option: Glaucoma

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Besser

Property Description
Active ingredient Dorzolamide and Timolol
Form Sterile Ophthalmic Solution (Eye Drops)
Pharmacological Class Ophthalmic Glaucoma Agent (Antiglaucoma Combination)
Common Use Reduction of Elevated Intraocular Pressure (IOP)
Origin Synthetic

Besser: A Fixed-Combination Prescription Eye Drop

Besser is a prescription-only medicinal product classified as an Ophthalmic Glaucoma Agent, administered as a sterile ophthalmic solution, or eye drop, for ocular (topical) use. The medication is specifically engineered as a fixed combination, meaning it unites two distinct active components—Dorzolamide and Timolol—in a single bottle. This design is widely clinically recognized for supporting patient adherence, as it simplifies the treatment regimen compared to administering two separate single-component eye drops sequentially.


Core Components and Pharmacological Class

The core of Besser's therapeutic action is the synergy between the two synthetic active ingredients, Dorzolamide and Timolol. Dorzolamide is classified as a topical carbonic anhydrase inhibitor, while Timolol is a topical beta-adrenergic receptor blocking agent, commonly known as a beta-blocker. Fixed combinations of these two agents are indicated for clinical use in patients requiring additional intraocular pressure reduction. This combination architecture is a key differentiating factor from monotherapies, as it guarantees the simultaneous application of two potent pharmacological mechanisms. The active compounds, present as Dorzolamide Hydrochloride and Timolol Maleate, are synthesized and dissolved within an aqueous solution base.


General Purpose: Dual Action for Elevated Intraocular Pressure (IOP) Control

The general purpose of Besser is to achieve a significant reduction in elevated intraocular pressure (IOP), which is the primary goal in managing conditions like open-angle glaucoma and ocular hypertension. This is achieved through the additive effect of its two components: Dorzolamide slows the formation of fluid, while Timolol further decreases the fluid production rate through a different mechanism. This dual mechanism provides effective pressure lowering. Besser is typically reserved for adult patients who have shown insufficient responsiveness to beta-blocker monotherapy, requiring the comprehensive, dual-pathway approach to safely reach the necessary ocular hypotensive outcome.

Regulatory References

  1. NIH/NEI Glaucoma Medicines

What side effects are possible with Besser?

Possible side effects and safety information

The fixed-combination ophthalmic solution contains Dorzolamide, a sulfonamide-derived agent, and Timolol, a beta-adrenergic blocking agent, which are absorbed systemically following topical ocular administration. Consequently, the official labeling documents indicate that systemic adverse reactions associated with both drug classes may potentially occur.


Adverse Reaction Categories

Very Common: The most frequent reactions reported in clinical studies include local ocular effects, specifically burning, stinging, or discomfort immediately following administration.

Common: Reactions occurring in 5% to 15% of patients include bitter or unusual taste (dysgeusia), conjunctival hyperemia (eye redness), superficial punctate keratitis, blurred vision, and eye itching. Less frequent reactions documented in official sources may involve headache, nausea, or dry eyes.

System-Organ Classes: Adverse events are classified by affected organ systems, including Eye Disorders, Nervous System Disorders, Cardiac Disorders, and Respiratory Disorders.


Serious Adverse Reactions and Safety Restrictions

Although rare, serious adverse reactions are documented. These include severe respiratory events, such as death due to bronchospasm in individuals with asthma, and death in association with cardiac failure. Additionally, the Dorzolamide component carries the potential for rare, severe sulfonamide reactions, such as Stevens-Johnson syndrome.

Safety is formally constrained by specific conditions. Use is contraindicated in patients with pre-existing bronchial asthma, severe Chronic Obstructive Pulmonary Disease (COPD), and certain severe cardiac conditions (e.g., sinus bradycardia, overt cardiac failure). The medication is also not recommended for use in individuals with severe renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of this fixed-combination ophthalmic solution is defined by the potential systemic effects of its two components, Dorzolamide and Timolol, which may result from accidental oral ingestion.

Documented Overdose Manifestations

Systemic absorption of the Timolol (beta-blocker) component can lead to bradycardia (slow heart rate), hypotension (low blood pressure), and cardiac failure. Severe outcomes listed in regulatory documents also include the potential for bronchospasm and dizziness. Overdose effects from the Dorzolamide (carbonic anhydrase inhibitor) component are characterized by acidosis, electrolyte imbalance, and nervous system effects, such as confusion or the potential for seizures.

Emergency Actions and Management

Official regulatory guidance mandates that patients seek immediate medical attention or contact emergency services if an overdose is suspected, especially if symptoms include difficulty breathing, severe slowness of the heart rate, or collapse. Management of an overdose is restricted to symptomatic and supportive treatment to stabilize vital functions, as regulatory information states that no specific antidote is known for this fixed combination. Continuous hospital monitoring is required for assessment of cardiovascular and respiratory status.

Therapeutic Uses of Besser

What Besser Treats: Main Uses and Benefits

The primary clinical application is the reduction of elevated intraocular pressure (IOP). This is relevant in the long-term management of chronic eye conditions, including Open-Angle Glaucoma and Ocular Hypertension, and is considered relevant when prior single-agent therapy may be insufficient.

This medication is applied in addressing situations where high pressure requires the use of two agents to help achieve a lower target IOP. The core benefit is support that helps ease the overall symptom burden by providing pressure stabilization, which assists with maintaining functional stability by addressing a key factor linked to visual changes. For patients requiring dual therapies, the fixed formulation supports the goal of patient adherence by simplifying the treatment regimen.

“The fixed combination is commonly used to help with pressure stabilization, especially when symptoms related to elevated IOP remain disruptive despite initial management.”


Quick Fact: Relief for Asymptomatic IOP Elevation

Besser is relevant for easing the challenges of maintaining long-term pressure control, which contributes to improved comfort during periods of heightened symptoms related to ocular stress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Besser?

The population eligibility for Besser (Dorzolamide/Timolol) is determined by regulatory agencies based on established contraindications and population-specific restrictions related to its two active components.

Contraindicated Populations

Use of this medicine is contraindicated in patients with specific pre-existing conditions, primarily due to the systemic effects of the topical beta-blocker (Timolol) and carbonic anhydrase inhibitor (Dorzolamide):

  • Respiratory Conditions: Patients with bronchial asthma, a history of asthma, or severe chronic obstructive pulmonary disease (COPD).
  • Cardiac Conditions: Patients with sinus bradycardia, second- or third-degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock.
  • Organ Function: Patients with severe renal impairment (Creatinine Clearance less than 30 mL/min) or hyperchloraemic acidosis.
  • Hypersensitivity: Individuals with known hypersensitivity to either active substance or any excipient.

Restricted and Not Recommended Populations

Population Group Eligibility Status (Regulatory Labeling)
Children/Adolescents (<18) Not Recommended (Efficacy/safety generally not established).
Pregnancy/Lactation Not Recommended (Safety not established; components secreted in milk).
Hepatic Impairment Use with Caution (Studies lacking; not recommended in severe cases).
Diabetes Mellitus Use with Caution (Beta-blockers can mask hypoglycemia signs).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns consistent with regulatory labeling for the Dorzolamide and Timolol combination.


Documented Pharmacodynamic and Systemic Effects

Co-administration with Systemic Beta-Adrenergic Blocking Agents may potentiate the effects of beta-blockade, increasing the risk of outcomes like marked bradycardia or hypotension when combined with medicines such as Oral Calcium Channel Blockers, Antiarrhythmics, and Catecholamine-Depleting Medicinal Products.

Regulatory documents formally state that Oral Carbonic Anhydrase Inhibitors are not recommended for co-administration due to the risk of additive systemic carbonic anhydrase inhibition. For patients on Antidiabetic Agents, the Timolol component may increase the hypoglycaemic effect.


Exposure and Administration Constraints

The simultaneous use of CYP2D6 Inhibitors (e.g., quinidine, fluoxetine) is documented to cause potentiated systemic beta-blockade due to reduced clearance of Timolol. The potential for toxicity associated with high-dose salicylate therapy must be considered due to the systemic absorption of the Dorzolamide component. A mandatory administration-timing rule requires separating Besser from other topical ophthalmic products by at least ten minutes. The product has not been studied in patients with hepatic impairment, which represents a population-specific interaction caution regarding altered drug exposure.

Mechanism of Action

How Besser Works

The dual mechanism acts on the ciliary processes to simultaneously employ two distinct, complementary pharmacological actions that reduce the rate of Aqueous Humor formation (inflow).


Enzyme-Mediated Suppression of Fluid Transport

The component Dorzolamide functions as an inhibitor of the enzyme Carbonic Anhydrase Isoenzyme II (CA-II). By blocking CA-II in the ciliary body, Dorzolamide suppresses the generation of bicarbonate ions ( HCO3^-) necessary for the active transport of sodium ( Na^+) and accompanying water. This interruption of the ion transport mechanism decreases the chemical rate of fluid secretion.


Receptor-Targeted Modulation of Secretory Signaling

Concurrently, Timolol functions as a non-selective antagonist (blocker) of beta-adrenergic receptors (beta1 and beta2) in the ciliary processes. By blocking these receptors, Timolol prevents stimulating sympathetic signals (catecholamines) from activating the cAMP signaling pathway. This action attenuates the neurohormonal stimulus that regulates the rate of fluid production, resulting in a reduced secretory flow.


Additive Physiological Effect on Fluid Inflow

The combination achieves an additive physiological effect because the two active ingredients modulate two entirely separate, yet converging, mechanisms—one enzymatic and one receptor-mediated—that both control the same outcome: the rate of Aqueous Humor formation. This simultaneous, dual-pathway suppression leads to a compounded reduction in the fluid volume produced, which modulates the pressure within the eye.

Dosage and Administration Information

How to Use Besser

Besser is a proprietary name, and the administration method depends entirely on the specific medication's formulation, route of delivery, and approved indication. Patients must follow the directions provided by their healthcare provider and those printed on the official drug labeling.

Never self-adjust the dose or schedule of administration. Using medication at a different dose or by an unapproved route can lead to serious health complications or even death.


General Administration Guidance

Factor Instructional Focus
Dosing Schedule Take the medication exactly as prescribed. Do not miss a dose or take extra doses.
Route of Administration Use only the route specified (e.g., oral, intravenous, subcutaneous). This ensures the drug is delivered correctly.
Preparation If the product requires mixing or is a suspension, follow preparation instructions precisely. Do not crush, chew, or divide tablets or capsules unless explicitly instructed by a healthcare professional or the product labeling.
Handling Always wash hands thoroughly before and after handling the medication.

Administration for Different Forms

Different drug forms necessitate specific handling. For example, some capsules containing drug beads are approved to be opened and the contents sprinkled onto soft food, such as applesauce, for patients who cannot swallow the intact capsule. However, it is crucial that these beads are swallowed whole and not chewed, as chewing can alter the drug's release characteristics and lead to unsafe or ineffective dosing, especially with modified-release formulations. Always consult the official package insert for guidance specific to your prescribed Besser product.

Recent Clinical Evidence

Evidence for use in Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT)

The core research for Besser involves Randomized Controlled Trials (RCTs) investigating its use in adult patients with Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT). Research primarily examines the absolute and relative change in Intraocular Pressure (IOP) from baseline, as this is the main endpoint researchers examine in these studies. Studies monitored patterns showing that the time of greatest measured IOP change was observed within the initial months of the study. The research examined measured IOP patterns when using the fixed combination compared to using its single-component ingredients on their own, contributing to the broader evidence landscape for both conditions.


Evidence in Patients with Insufficient Prior Control

This specific situation was evaluated using Comparative RCTs that employed a 'switch' or 'add-on' trial design. Research examined adult patients whose IOP was documented as being above the target range despite using a single-agent beta-blocker. The main outcome studied was the additional change in measured IOP observed after the patients transitioned to the fixed combination. Studies reported patterns that showed a further measured IOP change when the fixed combination was initiated after monotherapy was associated with IOP levels above target. The research described the switch of a majority of trial participants in these specific trial settings while researchers monitored measured IOP during this period.


Long-Term Research and Evidence Gaps

Research exploring the long-term measured IOP change extends beyond the initial six months of the core RCTs, primarily through open-label and Observational Studies. These studies monitored the IOP levels over one year or more, observing the evolution of measured IOP during that time. However, long-term effects are not fully established in the same high-certainty manner as the short-term IOP data. The main uncertainty centers on the lack of definitive evidence showing the specific long-term impact on functional outcomes, such as slowing the progression of visual field damage over many years. Data for specific patient groups, including pediatric populations, also remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Besser (FAQ)

Q: How quickly should I expect to feel an effect after starting Besser?

Studies indicate that the effect of the dorzolamide component in lowering pressure in the eye is typically measurable about two hours following administration. The time when the greatest overall pressure reduction was measured in clinical studies occurred within the initial months of treatment.

Q: How long does the effect of Besser last after taking a dose?

The necessity of twice daily administration reflects the duration of action required to maintain a reduction in intraocular pressure (IOP), according to official product information.

Q: Can Besser be taken by people with diabetes?

Official labeling contains a caution regarding the use of beta-blockers, such as the timolol component of Besser, in patients with diabetes. This is because the medication may mask some signs of low blood sugar (hypoglycemia), such as a rapid heart rate. This is a consideration noted in the labeling for people with diabetes.

Q: Does Besser interact with common over-the-counter pain relievers?

Regulatory documents state that the systemic absorption of the dorzolamide component warrants consideration of the potential for toxicity when combined with high-dose salicylate therapy (a type of pain reliever). Official product information does not explicitly address interactions with most common non-salicylate pain relievers.

Q: Are there any known issues with taking Besser and drinking alcohol?

Information suggests the timolol component may have an additive effect with alcohol (ethanol) in lowering blood pressure. This may be a consideration, potentially leading to symptoms such as dizziness or fainting, particularly when treatment is initiated.

Q: Do I need to stop taking any supplements while on Besser?

Official information notes that when the timolol component is used with some types of multivitamins that include minerals, the effect of the medication may be decreased. If this pattern occurs, a separation of administration times by at least two hours may be noted.

Q: How long does Besser stay in the body after the last dose?

Regulatory data shows that one of the drug's active components takes a long time to clear from the body. Following chronic use, the dorzolamide component is cleared from red blood cells slowly, with a terminal half-life estimated at about four months or more.

Q: What if Besser doesn't seem to be working for me after a few weeks?

Clinical studies show that the time of greatest measured IOP change was observed within the initial months of study. Because the full pressure-lowering effect may take time, the therapeutic response is intended to be monitored by a healthcare professional.

Q: Is Besser safe to take long-term, or is it only for short courses?

The product is indicated for the chronic management of elevated intraocular pressure. Research exploring long-term measured eye pressure change extends beyond the initial six months of clinical trials, primarily through observational studies, which contributes to the long-term evidence.

Q: Can Besser make me feel tired or dizzy?

Official adverse reaction reports document the possibility of feeling dizziness and fatigue/asthenia (unusual tiredness or weakness). These are potential systemic effects of the medication’s active ingredients.

Q: Is it normal to feel a mild headache when first starting Besser?

Headache is listed in official documents as an infrequently reported adverse reaction for the drug’s components. Not everyone experiences a headache, but it is a documented possibility.

Q: Are the side effects of Besser usually temporary?

Many local ocular adverse effects, such as allergic-type reactions in the eye or eyelid, were noted to resolve after the medication was stopped in studies. However, official sources do not make a general statement on the temporary nature of all possible side effects.

Q: What percentage of people experience side effects from Besser?

Clinical trials quantify the rates for specific common adverse reactions. For instance, approximately one-third of patients reported ocular burning or stinging, and about one-quarter of patients reported bitter taste.

Q: Is Besser a type of antibiotic?

No. Besser is classified by regulatory bodies as an Ophthalmic Glaucoma Agent. This combination product contains a carbonic anhydrase inhibitor and a beta-adrenergic receptor blocking agent, not an antibiotic.

Q: Can Besser affect my mood or energy levels?

Official adverse reaction reports include depression and rare psychiatric reactions such as insomnia (difficulty sleeping) and nightmares. These are reported effects associated with the drug’s components.

Q: Can Besser cause any vision changes?

Reported ocular adverse reactions include blurred vision, eye redness, and photophobia (increased sensitivity to light). These are documented possibilities that may occur following administration.

Q: Is Besser available generically?

Yes, regulatory records, such as the FDA's Approved Drug Products list (Orange Book), confirm that a generic version of the Dorzolamide Hydrochloride and Timolol Maleate combination ophthalmic solution has been approved.

Q: Are there any known long-term effects of using Besser for many years?

Long-term effects are not established in the same high-certainty manner as short-term data. The main uncertainty centers on definitive evidence regarding the long-term impact on functional outcomes, such as visual field damage.

Q: Can older adults use Besser safely?

Clinical trials included older patients (age 65 and over). Regulatory reviews found no overall differences in safety or effectiveness observed between these older patients and younger patients in the studies.

Q: Are there any documented cases of Besser overdose?

Official information describes symptoms potentially resulting from an accidental overdose. These effects can include confusion, dizziness, headache, bradycardia (slow heart rate), and shortness of breath.

Q: What is the expected duration of treatment with Besser?

The drug is indicated for the reduction of elevated intraocular pressure (IOP) in conditions like glaucoma and ocular hypertension. These conditions typically involve chronic, long-term monitoring and treatment.

Q: Is Besser known to cause drowsiness?

The label documents dizziness and fatigue/asthenia (unusual tiredness or weakness) as reported adverse reactions. These systemic effects may be related to feeling tired or sleepy.

How should Besser be stored and disposed of?

Besser (dorzolamide/timolol ophthalmic solution) must be stored strictly according to official regulatory requirements to maintain its stability.

Storage Requirements

Temperature: Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the product from freezing.

Protection: The medicine must be kept in its original container, tightly closed, and protected from light and excessive moisture. The container tip must not touch any surface.

Stability and Disposal

Single-Use: Any remaining solution in a single-dose container must be discarded immediately after use.

Child Safety: Keep Besser out of the sight and reach of children.

Disposal: Unused or expired medication must be disposed of according to local regulatory guidelines or official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Besser found in:

A-Z Index: